Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $89.17 USD
Change Today -0.50 / -0.56%
Volume 250.3K
As of 8:10 PM 05/26/15 All times are local (Market data is delayed by at least 15 minutes).

ligand pharmaceuticals (LGND) Snapshot

Open
$88.84
Previous Close
$89.67
Day High
$89.95
Day Low
$88.30
52 Week High
04/27/15 - $90.48
52 Week Low
10/9/14 - $41.99
Market Cap
1.8B
Average Volume 10 Days
309.0K
EPS TTM
$0.57
Shares Outstanding
19.7M
EX-Date
04/3/07
P/E TM
155.2x
Dividend
--
Dividend Yield
--
Current Stock Chart for LIGAND PHARMACEUTICALS (LGND)

ligand pharmaceuticals (LGND) Related Businessweek News

View More BusinessWeek News

ligand pharmaceuticals (LGND) Details

Ligand Pharmaceuticals Incorporated operates as a biotechnology company in the United States. The company’s commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis that is used for the treatment of multiple myeloma; bazedoxifene, which is used for the treatment of postmenopausal osteoporosis; and Captisol-enabled Noxafil-IV, a formulation of posaconazole for intravenous (IV) use. Its late-stage development programs include Captisol-enabled Melphalan IV, MK-8931 Beta-Secretase Inhibitor, Captisol-enabled SAGE-547, Sparsentan, Captisol-enabled Delafloxacin-IV, Captisol-enabled Carbamazepine-IV, IRAK4 Inhibitor Program, LTP Technology with Omega-3 Fatty Acids, Biologic Therapeutics Platform, Captisol-enabled Topiramate IV, Lasofoxifene, and Captisol-enabled Lamotrigine IV. The company’s internal product development programs include Glucagon Receptor Antagonist Program, Oral Human Granulocyte Colony Stimulating Factor Program, LTP Platform, Kinase Inhibitors, HepDirect HCV Inhibitor Program, and other programs. Its therapies in development portfolio addresses the unmet medical needs of patients for a range of diseases, including hepatitis, multiple myeloma, muscle wasting, Alzheimer’s disease, dyslipidemia, diabetes, anemia, epilepsy, focal segmental glomerulosclerosis, and osteoporosis. Ligand Pharmaceuticals Incorporated has alliances with GlaxoSmithKline, Amgen, Inc., Merck, Pfizer, Baxter International, and Eli Lilly and Co. The company was founded in 1987 and is headquartered in La Jolla, California.

19 Employees
Last Reported Date: 02/23/15
Founded in 1987

ligand pharmaceuticals (LGND) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: $510.2K
President and Chief Operating Officer
Total Annual Compensation: $375.4K
Vice President, General Counsel and Secretary
Total Annual Compensation: $288.9K
Compensation as of Fiscal Year 2014.

ligand pharmaceuticals (LGND) Key Developments

Ligand Pharmaceuticals Incorporated Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Provides Earnings Guidance for the Second Quarter 2015 and Affirms Earnings Guidance for the Full-Year 2015

Ligand Pharmaceuticals Incorporated announced unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company’s total revenues for the first quarter of 2015 were $14.602 million, compared with $15.958 million for the same period in 2014. Royalty revenues increased 31% to $10.287 million from $7.850 million for the same period in 2014 primarily due to higher royalties from Promacta and Kyprolis. Material sales were $3.729 million compared with $5.715 million for the same period in 2014 due to the timing of Captisol purchases for use in clinical trials. Collaborative research and development and other revenues were $0.6 million compared with $2.4 million for the same period in 2014 due primarily to significant milestones earned in the first quarter of 2014 from Merck for approval of Noxafil® and from Amgen for a Kyprolis sales milestone. Gain from operations was $3.349 million against $5.100 million a year ago. Net income for the first quarter of 2015 was $0.754 million, or $0.04 per basic and diluted share, compared with net income for the first quarter of 2014 of $2.097 million, or $0.10 per basic and diluted share. Adjusted net income from continuing operations for the first quarter of 2015 was $6.879 million, or $0.33 per diluted share, compared with adjusted net income from continuing operations for the first quarter of 2014 of $7.345 million, or $0.35 per diluted share. The company provided earnings guidance for the second quarter 2015 and affirmed earnings guidance for the full-year 2015. For the second quarter of 2015, the company expects total revenues to be between $17.0 million and $17.5 million, and adjusted earnings per diluted share to be between $0.37 and $0.40. Adjusted earnings per diluted share guidance exclude changes in contingent liabilities, mark-to-market adjustment for amounts owed to licensors, non-cash stock-based compensation expense and non-cash debt related costs. For the full year, the company currently affirms expectations for full-year 2015 total revenues to be between $81.0 million and $83.0 million, and adjusted earnings per diluted share to be between $2.14 and $2.18.

Ligand Pharmaceuticals Incorporated Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-12-2015 03:40 PM

Ligand Pharmaceuticals Incorporated Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-12-2015 03:40 PM. Venue: Encore at the Wynn, 3131 S Las Vegas Blvd, Las Vegas, Nevada, United States. Speakers: John L. Higgins, Chief Executive Officer and Executive Director.

Ligand Pharmaceuticals Incorporated, Q1 2015 Earnings Call, May 11, 2015

Ligand Pharmaceuticals Incorporated, Q1 2015 Earnings Call, May 11, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LGND:US $89.17 USD -0.50

LGND Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for LGND.
View Industry Companies
 

Industry Analysis

LGND

Industry Average

Valuation LGND Industry Range
Price/Earnings 100.0x
Price/Sales 27.8x
Price/Book 50.2x
Price/Cash Flow 165.1x
TEV/Sales 22.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LIGAND PHARMACEUTICALS, please visit www.ligand.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.